keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer clinical trials

keyword
https://www.readbyqxmd.com/read/29330287/targeted-akt-inhibition-in-prostate-cancer-cells-and-spheroids-reduces-aerobic-glycolysis-and-generation-of-hyperpolarized-1-13c-lactate
#1
Sui Seng Tee, Izabela Suster, Steven Truong, Sangmoo Jeong, Roozbeh Eskandari, Valentina Di Gialleonardo, Julio A Alvarez, Hannah N Aldeborgh, Kayvan Keshari
The PI3K/AKT/mTOR (PAM) signaling pathway is frequently mutated in prostate cancer. Specific AKT inhibitors are now in advanced clinical trials and this study investigates the effect of MK2206, a non-ATP competitive inhibitor, on the cellular metabolism in the context of prostate cancer. A significant reduction in cell motility and aerobic glycolysis was observed in prostate cancer cells with treatment. These changes were not accompanied by a reduction in the ratio of high-energy phosphates or a change in total protein levels of enzymes (e...
January 12, 2018: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/29330000/histotripsy-treatment-of-benign-prostatic-enlargement-using-the-vortx-rx-system-initial-human-safety-and-efficacy-outcomes
#2
T G Schuster, J T Wei, K Hendlin, R Jahnke, W W Roberts
OBJECTIVES: To assess clinical safety (primary) and efficacy (secondary) of histotripsy for treatment of symptomatic benign prostatic enlargement (BPE) in a first-in human study. METHODS: Twenty-five male subjects with moderate to severe lower urinary tract symptoms (LUTS), prostate size between 30 and 80 grams and no evidence of prostate cancer were enrolled at two sites in a prospective, single-arm study. Treatment consisted of acoustic energy delivery through the perineum with integrated real-time TRUS monitoring using the Vortx RX system...
January 9, 2018: Urology
https://www.readbyqxmd.com/read/29329996/to-prep-or-not-to-prep-that-is-the-question-a-randomized-trial-on-the-use-of-antiflatulent-medication-as-part-of-bowel-preparation-for-patients-having-image-guided-external-beam-radiation-therapy-to-the-prostate
#3
Merrylee McGuffin, Naila Devji, Lyann Kehoe, Anne Carty, Steve Russell, Lisa Di Prospero, Carlo DeAngelis, Alex Kiss, Danny Vesprini, Andrew Loblaw, Laura D'Alimonte
INTRODUCTION: Radiation therapy is a standard treatment option for prostate cancer. With growing use of escalated doses and tighter margins, procedures to limit rectal size variation are needed to reduce prostate motion, increase treatment accuracy, and minimize rectal toxicity. This prospective study was done to determine whether the introduction of an antiflatulent medication would decrease rectal distention at computed tomography (CT) simulation and throughout a course of radiation therapy...
November 4, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29326030/patient-reported-outcomes-following-abiraterone-acetate-plus-prednisone-added-to-androgen-deprivation-therapy-in-patients-with-newly-diagnosed-metastatic-castration-naive-prostate-cancer-latitude-an-international-randomised-phase-3-trial
#4
Kim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, Gaetano Facchini, Henrik Suttman, Nobuaki Matsubara, Zhangqun Ye, Bhumsuk Keam, Ronaldo Damião, Tracy Li, Kelly McQuarrie, Bin Jia, Peter De Porre, Jason Martin, Mary B Todd, Karim Fizazi
BACKGROUND: In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer. Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) is important for treatment decisions; therefore we aimed to analyse the effects of ADT plus abiraterone acetate and prednisone versus ADT plus placebos on PROs and HRQOL in patients in the LATITUDE study...
January 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29323792/the-retinamide-vnlg-152-inhibits-ar-ar-v7-and-mnk-eif4esignaling-pathways-to-suppress-emt-and-castration-resistant-prostate-cancer-xenograft-growth
#5
Vidya P Ramamurthy, Senthilmurugan Ramalingam, Lalji K Gediya, Vincent C O Njar
VNLG-152, a lead novel retinamide (NR) shown to suppress growth and progression in genetically diverse PCa cells via inhibition of AR signaling and eIF4E translational machinery. Herein, we report therapeutic effects of VNLG-152 on castration resistant prostate cancer (CRPC) growth and metastatic phenotype in CRPC tumor xenograft model. Administration of VNLG-152 significantly and dose-dependently suppressed the growth of aggressive CWR22Rv1 tumors by 63.4% and 76.3% respectively (P = 0.001), vs. vehicle with no host toxicity...
January 11, 2018: FEBS Journal
https://www.readbyqxmd.com/read/29318656/circadian-genes-and-risk-of-prostate-cancer-in-the-prostate-cancer-prevention-trial
#6
Lisa W Chu, Cathee Till, Baiyu Yang, Catherine M Tangen, Phyllis J Goodman, Kai Yu, Yong Zhu, Summer Han, Ashraful M Hoque, Christine Ambrosone, Ian Thompson, Robin Leach, Ann W Hsing
Circadian genes have been considered as a possible biological mechanism for the observed relationship between circadian rhythm disruptions and increased risk of hormone-related cancers. In the current study, we investigated the relationship between circadian gene variants and prostate cancer risk and whether reducing bioavailable testosterone modifies the circadian genes-prostate cancer relationship. We conducted a nested case-control study among Caucasian men in the Prostate Cancer Prevention Trial (PCPT), a randomized placebo-controlled clinical trial to assess if finasteride (an androgen bioactivation inhibitor) could prevent prostate cancer...
January 10, 2018: Molecular Carcinogenesis
https://www.readbyqxmd.com/read/29314169/correlations-of-selenof-and-selenop-genotypes-with-serum-selenium-levels-and-prostate-cancer
#7
Dede N Ekoue, Emmanuel Ansong, Li Liu, Virgilia Macias, Ryan Deaton, Craig Lacher, Matthew Picklo, Larisa Nonn, Peter H Gann, Andre Kajdacsy-Balla, Gail S Prins, Vincent L Freeman, Alan M Diamond
BACKGROUND: Selenium status is inversely associated with the incidence of prostate cancer. However, supplementation trials have not indicated a benefit of selenium supplementation in reducing cancer risk. Polymorphisms in the gene encoding selenoprotein 15 (SELENOF) are associated with cancer incidence/mortality and present disproportionately in African Americans. Relationships among the genotype of selenoproteins implicated in increased cancer risk, selenium status, and race with prostate cancer were investigated...
January 5, 2018: Prostate
https://www.readbyqxmd.com/read/29310183/re-surrogate-end-points-for-all-cause-mortality-in-men-with-localized-unfavorable-risk-prostate-cancer-treated-with-radiation-therapy-vs-radiation-therapy-plus-androgen-deprivation-therapy-a-secondary-analysis-of-a-randomized-clinical-trial
#8
https://www.readbyqxmd.com/read/29306514/intermediate-endpoints-after-postprostatectomy-radiotherapy-5-year-distant-metastasis-to-predict-overall-survival
#9
William C Jackson, Krithika Suresh, Vasu Tumati, Steven G Allen, Robert T Dess, Simpa S Salami, Arvin George, Samuel D Kaffenberger, David C Miller, Jason W D Hearn, Shruti Jolly, Rohit Mehra, Brent K Hollenbeck, Ganesh S Palapattu, Matthew Schipper, Felix Y Feng, Todd M Morgan, Neil B Desai, Daniel E Spratt
BACKGROUND: Intermediate clinical endpoints (ICEs) prognostic for overall survival (OS) are needed for men receiving postprostatectomy radiation therapy (PORT) to improve clinical trial design. OBJECTIVE: To identify a potential ICE for men receiving PORT. DESIGN, SETTING, AND PARTICIPANTS: We performed an institutional review board-approved multi-institutional retrospective study of 566 men consecutively treated with PORT at tertiary care centers from 1986 to 2013...
January 3, 2018: European Urology
https://www.readbyqxmd.com/read/29304991/a-multi-institutional-phase-2-trial-of-prostate-stereotactic-body-radiation-therapy-sbrt-using-continuous-real-time-evaluation-of-prostate-motion-with-patient-reported-quality-of-life
#10
William C Jackson, Robert T Dess, Dale W Litzenberg, Pin Li, Matthew Schipper, Seth A Rosenthal, Garrick C Chang, Eric M Horwitz, Robert A Price, Jeff M Michalski, Hiram A Gay, John T Wei, Mary Feng, Felix Y Feng, Howard M Sandler, Robert E Wallace, Daniel E Spratt, Daniel A Hamstra
PURPOSE: The use of stereotactic body radiation therapy (SBRT) for prostate cancer has been reported predominantly from single institutional studies, although concerns for broader adoption exist. METHODS AND MATERIALS: From 2011 through 2013, 66 men were accrued to a phase 2 trial at 5 centers. SBRT consisted of 5 fractions of 7.4 Gy to a total dose of 37 Gy using conventional linear accelerators. Electromagnetic transponders were used for motion management. Health-related quality of life (HRQOL) was evaluated via the Expanded Prostate Cancer Index Composite 26 questionnaire...
January 2018: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29301928/the-utility-of-pet-ct-in-external-radiation-therapy-planning-of-prostate-cancer
#11
Jeremie Calais, Minsong Cao, Nicholas G Nickols
Radiotherapy and radical prostatectomy are the definitive treatment options for patients with localized prostate cancer. A rising PSA after radical prostatectomy indicates prostate cancer recurrence, and these patients may still be cured with salvage radiotherapy. To maximize chance for cure, irradiated volumes should completely encompass the extent of disease. Therefore, accurate estimation of the location of disease is critical for radiotherapy planning in both the definitive and salvage settings. Conventional imaging for prostate cancer has limited sensitivity for detection of disease both at initial staging and at biochemical recurrence...
January 4, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29300184/correlations-between-contouring-similarity-metrics-and-simulated-treatment-outcome-for-prostate-radiotherapy
#12
Dale Roach, Michael G Jameson, Jason A Dowling, Martin Andrew Ebert, Peter B Greer, Angel M Kennedy, Sandie Watt, Lois C Holloway
Many similarity metrics exist for inter-observer contouring variation studies, however no correlation between metric choice and prostate cancer radiotherapy dosimetry has been explored. These correlations were investigated in this study. Two separate trials were undertaken, the first a thirty-five patient cohort with three observers, the second a five patient dataset with ten observers. Clinical and planning target volumes (CTV and PTV), rectum, and bladder were independently contoured by all observers in each trial...
January 4, 2018: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/29298991/current-approaches-to-incorporation-of-radium-223-in-clinical-practice
#13
REVIEW
Chris Parker, Axel Heidenreich, Sten Nilsson, Neal Shore
BACKGROUND: Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years and include cytotoxic agents (e.g., docetaxel and cabazitaxel), immunotherapy (e.g., sipuleucel-T), oral hormonal therapies targeting the androgen receptor axis (e.g., enzalutamide and abiraterone), and targeted alpha therapy (e.g., radium-223 dichloride (radium-223)). Although treatment guidelines have been updated to reflect the availability of new agents, it is not easy to apply them in daily clinical practice because recommendations vary depending on patient comorbidities and disease characteristics...
January 3, 2018: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/29297495/treatment-effects-in-prostate-cancer
#14
Andrew J Evans
Nonsurgical treatments for prostate cancer include androgen-deprivation therapy (ADT), radiation therapy (RT), ablative therapies, chemotherapy, and newly emerging immunotherapies. These approaches can be used alone or in combination depending on the clinical scenario. ADT is typically reserved for high-risk locally or systemically advanced disease that is not amenable to curative surgery. Radiation therapy can be used instead of surgery as primary therapy with curative intent for low-intermediate-risk disease as well as for control of locally advanced disease not suitable for surgery...
January 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/29290963/prognostic-factors-in-men-with-metastatic-castration-resistant-prostate-cancer-treated-with-cabazitaxel
#15
Bodine P S Belderbos, Ronald de Wit, Esther Oomen-de Hoop, Annemieke Nieuweboer, Paul Hamberg, Robbert J van Alphen, André Bergman, Nelly van der Meer, Sander Bins, Ron H J Mathijssen, Robert J van Soest
Background: Treatment selection for men with metastatic castration-resistant prostate cancer (mCRPC) has become increasingly challenging with the introduction of novel therapies at earlier disease stages. The purpose of this study was to identify prognostic factors for overall survival (OS) and PSA response in patients with mCRPC treated with cabazitaxel. Results: 224 mCRPC patients were included in the current analysis. In multivariable analysis, WHO performance status, baseline hemoglobin, alkaline phosphatase and albumin were all significantly associated with OS...
December 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/29288137/a-prospective-cohort-and-extended-comprehensive-cohort-design-provided-insights-about-the-generalizability-of-a-pragmatic-trial-the-protect-prostate-cancer-trial
#16
Jenny L Donovan, Grace J Young, Eleanor I Walsh, Chris Metcalfe, J Athene Lane, Richard M Martin, Marta K Tazewell, Michael Davis, Tim J Peters, Emma L Turner, Nicola Mills, Hanan Khazragui, Tarnjit K Khera, David E Neal, Freddie C Hamdy
OBJECTIVES: Randomized controlled trials (RCTs) deliver robust internally valid evidence but generalizability is often neglected. Design features built into the ProtecT RCT of treatments for localized prostate cancer (PCa) provided insights into its generalizability. STUDY DESIGN AND SETTING: Population-based cluster-randomization created a prospective study of PSA-testing and a comprehensive-cohort study including groups choosing treatment or excluded from the RCT, as well as those randomized...
December 26, 2017: Journal of Clinical Epidemiology
https://www.readbyqxmd.com/read/29283440/cabozantinib-a-multi-targeted-oral-tyrosine-kinase-inhibitor
#17
Jordan N Markowitz, Karen M Fancher
Cabozantinib is an oral, small-molecule, multitargeted tyrosine kinase inhibitor (TKI) that may confer an advantage over other TKIs that target a single receptor. It has been approved by the United States Food and Drug Administration for the treatment of both advanced renal cell carcinoma and progressive metastatic medullary thyroid cancer, and is being investigated for a wide array of other malignancies. Rationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article...
December 28, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/29282518/current-status-of-theranostics-in-prostate-cancer
#18
REVIEW
Irene Virgolini, Clemens Decristoforo, Alexander Haug, Stefano Fanti, Christian Uprimny
The aim of this review is to report on the current status of prostate-specific membrane antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of 68Ga-PSMA-directed PET imaging as a diagnostic procedure for primary and recurrent PC as well as the role of evolving PSMA radioligand therapy (PRLT) in castration-resistant (CR)PC is assessed. The most eminent data from mostly retrospective studies currently available on theranostics of prostate cancer are discussed. The current knowledge on 68Ga-PSMA PET/CT implicates that primary staging with PET/CT is meaningful in patients with high-risk PC and that the combination with pelvic multi parametric (mp)MR (or PET/mpMR) reaches the highest impact on patient management...
December 28, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29281868/positive-effects-of-cognitive-behavioral-therapy-on-depression-anxiety-and-stress-of-family-caregivers-of-patients-with-prostate-cancer-a-randomized-clinical-trial
#19
Milad Borji, Hassan Nourmohammadi, Masoumeh Otaghi, Amir Hosein Salimi, Asma Tarjoman
Background: The family caregivers of patients with cancer mightexperience various physical, mental, and spiritual difficulties, the neglect of which can causeseriousproblems for theentirefamily. If caregivers are left without appropriate treatment and intervention, their level of physical and mental health will substantially decrease-they will, in other words, become“hidden patients.” Materials and Methods: The current study is a clinical trial of 80 family caregivers of patients with prostate cancer, who were allocated to control and experimental groups...
December 28, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29280452/conventional-versus-hypofractionated-radiation-therapy-for-localized-or-locally-advanced-prostate-cancer-a-systematic-review-and-meta-analysis-along-with-therapeutic-implications
#20
REVIEW
Niloy R Datta, Emanuel Stutz, Susanne Rogers, Stephan Bodis
PURPOSE: A systematic review and meta-analysis were conducted to evaluate the therapeutic outcomes of conventional radiation therapy (CRT) and hypofractionated radiation therapy (HRT) for localized or locally advanced prostate cancer (LLPCa). METHODS AND MATERIALS: A total of 599 abstracts were extracted from 5 databases and screened in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Only phase III trials randomized between CRT and HRT in LLPCa with a minimum of 5 years of follow-up data were considered...
November 1, 2017: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
58398
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"